Simultaneous Analysis of Dapsone and Monoacetyldapsone Employing High Performance Liquid Chromatography: a Rapid Method for Determination of Acetylator Phenotype

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1978 Nov 1

PMID 728285

Citations 25

Authors

K Carr

J A OATES

A S Nies

R L Woosley

Affiliations

Soon will be listed here.

Abstract

1 A rapid, accurate and convenient technique for determination of acetylator phenotype of patients or subjects has not been available for routine clinical application. 2 An improved method for rapid and convenient determination of acetylator phenotype is described. 3 The plasma concentrations of dapsone (DDS) and monoacetyldapsone (MAD) were measured 3 h after a single oral 100 mg dose of dapsone using a specific and sensitive high performance liquid chromatographic assay. 4 The plasma concentration ratio of monoacetyldapsone to dapsone can accurately assess acetylator phenotype in patients or subjects. 5 The clinical applications for this method are discussed.

Citing Articles

Assessment of liver metabolic function. Clinical implications.

Brockmoller J, Roots I Clin Pharmacokinet. 1994; 27(3):216-48.

PMID: 7988103 DOI: 10.2165/00003088-199427030-00005.

Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.

Falloon J, Lavelle J, Ogata-Arakaki D, Byrne A, Graziani A, Morgan A Antimicrob Agents Chemother. 1994; 38(7):1580-7.

PMID: 7979291 PMC: 284596. DOI: 10.1128/AAC.38.7.1580.

Evaluation of effects of altered gastric pH on absorption of dapsone in healthy volunteers.

Breen G, Brocavich J, Etzel J, Shah V, Schaefer P, Forlenza S Antimicrob Agents Chemother. 1994; 38(9):2227-9.

PMID: 7811056 PMC: 284721. DOI: 10.1128/AAC.38.9.2227.

Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.

Vree T, OREILLY W, Hekster Y, Damsma J, van der Kleijn E Clin Pharmacokinet. 1980; 5(3):274-94.

PMID: 7389236 DOI: 10.2165/00003088-198005030-00006.

Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.

Ahmad R, Rogers H Eur J Clin Pharmacol. 1980; 17(2):129-33.

PMID: 7371704 DOI: 10.1007/BF00562621.

References

Reidenberg M, Drayer D, DeMarco A, BELLO C . Hydralazine elimination in man. Clin Pharmacol Ther. 1973; 14(6):970-7. DOI: 10.1002/cpt1973146970. View

Das K, Eastwood M . Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther. 1975; 18(5 Pt 1):514-20. DOI: 10.1002/cpt1975185part1514. View

Reidenberg M, Drayer D, Levy M, Warner H . Polymorphic acetylation procainamide in man. Clin Pharmacol Ther. 1975; 17(6):722-30. DOI: 10.1002/cpt1975176722. View

Lower Jr G, Bryan G . Enzymatic N-acetylation of carcinogenic aromatic amines by liver cytosol of species displaying different organ susceptibilities. Biochem Pharmacol. 1973; 22(13):1581-8. DOI: 10.1016/0006-2952(73)90024-5. View

Zacest R, Koch-Weser J . Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther. 1972; 13(3):420-5. DOI: 10.1002/cpt1972133420. View

PERRY Jr H, Tan E, Carmody S, Sakamoto A . Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med. 1970; 76(1):114-25. View

Alarcon-Segovia D, FISHBEIN E, Alcala H . Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment. Arthritis Rheum. 1971; 14(6):748-52. DOI: 10.1002/art.1780140610. View

DEGOWIN R, EPPES R, Powell R, Carson P . The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull World Health Organ. 1966; 35(2):165-79. PMC: 2476117. View

Elson J, Strong J, Lee W, Atkinson Jr A . Antiarrhythmic potency of N-acetylprocainamide. Clin Pharmacol Ther. 1975; 17(2):134-40. DOI: 10.1002/cpt1975172134. View

10.

Murray Jr J, Gordon G, Peters J . A chromatographic-fluorometric procedure for the determination of nanogram quantities of antileprotic sulfones. J Lab Clin Med. 1971; 78(3):464-71. View

11.

Gelber R, Peters J, Gordon G, GLAZKO A, Levy L . The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971; 12(2):225-38. DOI: 10.1002/cpt1971122part1225. View

12.

Peters J, Gordon G, Colwell Jr W . The fluorometric measurement of 4,4'-diaminodiphenyl sulfone and its acetylated derivatives in plasma and urine. J Lab Clin Med. 1970; 76(2):338-48. View

13.

Mattila M, Tiitinen H, Alhava E . Acetylation pattern of different sulphonamides in rapid and slow isoniazid inactivators. Ann Med Exp Biol Fenn. 1969; 47(4):308-15. View

14.

Evans D . An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969; 6(4):405-7. PMC: 1468783. DOI: 10.1136/jmg.6.4.405. View

15.

Scott E, Wright R, Weaver D . The discrimination of phenotypes for rate of disappearance of isonicotinoyl hydrazide from serum. J Clin Invest. 1969; 48(7):1173-6. PMC: 322338. DOI: 10.1172/JCI106081. View

16.

GLAZKO A, DILL W, Montalbo R, Holmes E . A new analytical procedure for dapsone. Application to blood-level and urinary-excretion studies in normal men. Am J Trop Med Hyg. 1968; 17(3):465-73. View

17.

Ellard G . Absorption, metabolism and excretion of di(rho-aminophenyl) sulphone (dapsone) and di(rho-aminophenyl) sulphoxide in man. Br J Pharmacol Chemother. 1966; 26(1):212-7. PMC: 1510771. DOI: 10.1111/j.1476-5381.1966.tb01823.x. View

18.

Evans D, MANLEY K, MCKUSICK V . Genetic control of isoniazid metabolism in man. Br Med J. 1960; 2(5197):485-91. PMC: 2097108. DOI: 10.1136/bmj.2.5197.485. View

19.

Evans D, DAVISON K, PRATT R . THE INFLUENCE OF ACETYLATOR PHENOTYPE ON THE EFFECTS OF TREATING DEPRESSION WITH PHENELZINE. Clin Pharmacol Ther. 1965; 6:430-5. DOI: 10.1002/cpt196564430. View

20.

Dufour A, Knight R, Harris H . GENETICS OF ISONIAZID METABOLISM IN CAUCASIAN, NEGRO, AND JAPANESE POPULATIONS. Science. 1964; 145(3630):391. View